Cargando…
Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report
Daily oral synthetic levothyroxine (LT4) is the main treatment for hypothyroidism, which, in most cases, allows the regression of symptoms and the normalization of the thyroid function. However, rarely, despite a high dose of oral LT4, hypothyroidism persists and is called refractory hypothyroidism....
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239661/ https://www.ncbi.nlm.nih.gov/pubmed/35777000 http://dx.doi.org/10.1097/MD.0000000000029690 |
_version_ | 1784737352512438272 |
---|---|
author | Naman, Annabelle Delemer, Brigitte Marot, Didier Michelet, Elise Decoudier, Bénédicte Barraud, Sara |
author_facet | Naman, Annabelle Delemer, Brigitte Marot, Didier Michelet, Elise Decoudier, Bénédicte Barraud, Sara |
author_sort | Naman, Annabelle |
collection | PubMed |
description | Daily oral synthetic levothyroxine (LT4) is the main treatment for hypothyroidism, which, in most cases, allows the regression of symptoms and the normalization of the thyroid function. However, rarely, despite a high dose of oral LT4, hypothyroidism persists and is called refractory hypothyroidism. Intravenous or intramuscular treatment is then often necessary. We report the case of a patient with refractory hypothyroidism successfully treated with subcutaneous LT4. INTERVENTIONS AND OUTCOMES: After 4 weeks of weekly intravenous injections of 200 µg LT4 in complement to the oral treatment, thyroid balance was improved (TSH: 21.8 mIU/L). We tested the replacement of intravenous with subcutaneous injections of LT4 and gradually increased injection frequency from 1 to 3 injections per week (600 µg/week). Simultaneously, oral treatment was gradually tapered off, and within a few months, thyroid function tests were normalized. Two years later, hormone levels remained normal without symptoms of hypothyroidism. The only side effect was a local reaction in the first few weeks of injections, which spontaneously resolved. LESSONS: In this case of unexplained oral LT4 malabsorption, subcutaneous injection allowed a self-administrated physiological dose of LT4 3 times weekly. Considering the efficacy of subcutaneous injection of LT4, this treatment could be a safe and easy alternative for patients with malabsorption. |
format | Online Article Text |
id | pubmed-9239661 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-92396612022-06-30 Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report Naman, Annabelle Delemer, Brigitte Marot, Didier Michelet, Elise Decoudier, Bénédicte Barraud, Sara Medicine (Baltimore) Research Article Daily oral synthetic levothyroxine (LT4) is the main treatment for hypothyroidism, which, in most cases, allows the regression of symptoms and the normalization of the thyroid function. However, rarely, despite a high dose of oral LT4, hypothyroidism persists and is called refractory hypothyroidism. Intravenous or intramuscular treatment is then often necessary. We report the case of a patient with refractory hypothyroidism successfully treated with subcutaneous LT4. INTERVENTIONS AND OUTCOMES: After 4 weeks of weekly intravenous injections of 200 µg LT4 in complement to the oral treatment, thyroid balance was improved (TSH: 21.8 mIU/L). We tested the replacement of intravenous with subcutaneous injections of LT4 and gradually increased injection frequency from 1 to 3 injections per week (600 µg/week). Simultaneously, oral treatment was gradually tapered off, and within a few months, thyroid function tests were normalized. Two years later, hormone levels remained normal without symptoms of hypothyroidism. The only side effect was a local reaction in the first few weeks of injections, which spontaneously resolved. LESSONS: In this case of unexplained oral LT4 malabsorption, subcutaneous injection allowed a self-administrated physiological dose of LT4 3 times weekly. Considering the efficacy of subcutaneous injection of LT4, this treatment could be a safe and easy alternative for patients with malabsorption. Lippincott Williams & Wilkins 2022-06-30 /pmc/articles/PMC9239661/ /pubmed/35777000 http://dx.doi.org/10.1097/MD.0000000000029690 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Naman, Annabelle Delemer, Brigitte Marot, Didier Michelet, Elise Decoudier, Bénédicte Barraud, Sara Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report |
title | Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report |
title_full | Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report |
title_fullStr | Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report |
title_full_unstemmed | Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report |
title_short | Efficacy of subcutaneous Levothyroxine in a case of refractory hypothyroidism: A case report |
title_sort | efficacy of subcutaneous levothyroxine in a case of refractory hypothyroidism: a case report |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239661/ https://www.ncbi.nlm.nih.gov/pubmed/35777000 http://dx.doi.org/10.1097/MD.0000000000029690 |
work_keys_str_mv | AT namanannabelle efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport AT delemerbrigitte efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport AT marotdidier efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport AT micheletelise efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport AT decoudierbenedicte efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport AT barraudsara efficacyofsubcutaneouslevothyroxineinacaseofrefractoryhypothyroidismacasereport |